326 related articles for article (PubMed ID: 7168557)
1. Effect of tamoxifen treatment on estrogen metabolism in postmenopausal women with advanced breast cancer.
Levin J; Markham MJ; Greenwald ES; O'Connor JF; Zumoff B; Fukushima DK
Anticancer Res; 1982; 2(6):377-80. PubMed ID: 7168557
[TBL] [Abstract][Full Text] [Related]
2. Relationship between urine and plasma estrogen ratios.
Longcope C; Pratt JH
Cancer Res; 1978 Nov; 38(11 Pt 2):4025-8. PubMed ID: 698950
[TBL] [Abstract][Full Text] [Related]
3. Effects of tamoxifen on testosterone metabolism in postmenopausal women with breast cancer.
Bird CE; Masters V; Sterns EE; Clark AF
Clin Invest Med; 1985; 8(2):97-102. PubMed ID: 2938865
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum estrogen levels in women during tamoxifen therapy.
Lum SS; Woltering EA; Fletcher WS; Pommier RF
Am J Surg; 1997 May; 173(5):399-402. PubMed ID: 9168075
[TBL] [Abstract][Full Text] [Related]
5. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture.
Lippman M; Monaco ME; Bolan G
Cancer Res; 1977 Jun; 37(6):1901-7. PubMed ID: 870192
[TBL] [Abstract][Full Text] [Related]
6. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
Wilking N; Carlström K; Sköldefors H; Theve NO; Wallgren A
Acta Chir Scand; 1982; 148(4):345-9. PubMed ID: 6215811
[TBL] [Abstract][Full Text] [Related]
7. Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer.
Morreal CE; Dao TL; Nemoto T; Lonergan PA
J Natl Cancer Inst; 1979 Nov; 63(5):1171-4. PubMed ID: 291747
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease.
Reed MJ; Cheng RW; Noel CT; Dudley HA; James VH
Cancer Res; 1983 Aug; 43(8):3940-3. PubMed ID: 6683128
[TBL] [Abstract][Full Text] [Related]
9. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects.
Helgason S
Acta Obstet Gynecol Scand Suppl; 1982; 107():1-29. PubMed ID: 6282033
[TBL] [Abstract][Full Text] [Related]
10. Abnormal estrogen conjugation in women at risk for familial breast cancer at the periovulatory stage of the menstrual cycle.
Fishman J; Bradlow HL; Fukushima DK; O'Connor J; Rosenfeld RS; Graepel GJ; Elston R; Lynch H
Cancer Res; 1983 Apr; 43(4):1884-90. PubMed ID: 6831424
[TBL] [Abstract][Full Text] [Related]
11. Effect of diet on excretion of estrogens in pre- and postmenopausal women.
Goldin BR; Adlercreutz H; Dwyer JT; Swenson L; Warram JH; Gorbach SL
Cancer Res; 1981 Sep; 41(9 Pt 2):3771-3. PubMed ID: 7260944
[TBL] [Abstract][Full Text] [Related]
12. Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.
Lønning PE; Kvinnsland S; Thorsen T; Ekse D
Breast Cancer Res Treat; 1986; 7 Suppl():S77-82. PubMed ID: 3742065
[TBL] [Abstract][Full Text] [Related]
13. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
15. Estrogen profiles of premenopausal women with breast cancer.
Cole P; Cramer D; Yen S; Paffenbarger R; MacMahon B; Brown J
Cancer Res; 1978 Mar; 38(3):745-8. PubMed ID: 626978
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement with estradiol: conventional oral doses result in excessive exposure to estrone.
Friel PN; Hinchcliffe C; Wright JV
Altern Med Rev; 2005 Mar; 10(1):36-41. PubMed ID: 15771561
[TBL] [Abstract][Full Text] [Related]
17. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
18. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
19. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
20. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
